### Medicare Chronic Condition Counts

**Table B.2.b.** Medicare beneficiary prevalence* for other chronic or disabling conditions** using fee-for-service (FFS) claims, 2012–2021

<table>
<thead>
<tr>
<th>Other chronic or disabling condition**</th>
<th>2012 numerator‡</th>
<th>2012 rate</th>
<th>2013 numerator‡</th>
<th>2013 rate</th>
<th>2014 numerator‡</th>
<th>2014 rate</th>
<th>2015 numerator‡</th>
<th>2015 rate</th>
<th>2016 numerator‡</th>
<th>2016 rate</th>
</tr>
</thead>
<tbody>
<tr>
<td>ADHD, conduct disorders, and hyperkinetic syndrome</td>
<td>248,851</td>
<td>0.8%</td>
<td>271,841</td>
<td>0.8%</td>
<td>293,342</td>
<td>0.9%</td>
<td>317,658</td>
<td>1.0%</td>
<td>333,252</td>
<td>1.0%</td>
</tr>
<tr>
<td>Alcohol use disorders</td>
<td>604,040</td>
<td>1.9%</td>
<td>632,009</td>
<td>2.0%</td>
<td>649,963</td>
<td>2.0%</td>
<td>698,051</td>
<td>2.2%</td>
<td>797,387</td>
<td>2.4%</td>
</tr>
<tr>
<td>Anxiety disorders</td>
<td>3,721,714</td>
<td>11.7%</td>
<td>4,134,362</td>
<td>12.9%</td>
<td>4,435,133</td>
<td>13.8%</td>
<td>4,814,382</td>
<td>15.0%</td>
<td>5,346,168</td>
<td>16.4%</td>
</tr>
<tr>
<td>Autism spectrum disorders</td>
<td>43,617</td>
<td>0.1%</td>
<td>49,486</td>
<td>0.2%</td>
<td>55,314</td>
<td>0.2%</td>
<td>62,340</td>
<td>0.2%</td>
<td>71,621</td>
<td>0.2%</td>
</tr>
<tr>
<td>Bipolar disorder</td>
<td>1,033,503</td>
<td>3.2%</td>
<td>1,076,945</td>
<td>3.4%</td>
<td>1,098,958</td>
<td>3.4%</td>
<td>1,124,472</td>
<td>3.5%</td>
<td>1,155,688</td>
<td>3.5%</td>
</tr>
<tr>
<td>Cerebral palsy</td>
<td>105,810</td>
<td>0.3%</td>
<td>107,704</td>
<td>0.3%</td>
<td>108,769</td>
<td>0.3%</td>
<td>110,363</td>
<td>0.3%</td>
<td>114,630</td>
<td>0.4%</td>
</tr>
<tr>
<td>Cystic fibrosis and other metabolic developmental disorders</td>
<td>155,189</td>
<td>0.5%</td>
<td>162,041</td>
<td>0.5%</td>
<td>174,283</td>
<td>0.5%</td>
<td>209,847</td>
<td>0.7%</td>
<td>260,333</td>
<td>0.8%</td>
</tr>
<tr>
<td>Depressive disorders</td>
<td>4,927,609</td>
<td>15.4%</td>
<td>5,111,608</td>
<td>15.9%</td>
<td>5,258,316</td>
<td>16.4%</td>
<td>5,425,067</td>
<td>16.9%</td>
<td>5,516,712</td>
<td>16.9%</td>
</tr>
<tr>
<td>Drug use disorders</td>
<td>616,023</td>
<td>1.9%</td>
<td>665,110</td>
<td>2.1%</td>
<td>713,350</td>
<td>2.2%</td>
<td>818,499</td>
<td>2.5%</td>
<td>1,020,399</td>
<td>3.1%</td>
</tr>
<tr>
<td>Epilepsy</td>
<td>805,605</td>
<td>2.5%</td>
<td>826,690</td>
<td>2.6%</td>
<td>834,433</td>
<td>2.6%</td>
<td>848,574</td>
<td>2.6%</td>
<td>893,338</td>
<td>2.7%</td>
</tr>
<tr>
<td>Fibromyalgia, chronic pain, and fatigue</td>
<td>3,541,648</td>
<td>11.1%</td>
<td>3,769,733</td>
<td>11.7%</td>
<td>3,994,484</td>
<td>12.5%</td>
<td>4,671,360</td>
<td>14.5%</td>
<td>6,045,548</td>
<td>18.5%</td>
</tr>
<tr>
<td>Human immunodeficiency virus and/or acquired immunodeficiency syndrome (HIV/AIDS)</td>
<td>119,958</td>
<td>0.4%</td>
<td>121,996</td>
<td>0.4%</td>
<td>121,620</td>
<td>0.4%</td>
<td>120,572</td>
<td>0.4%</td>
<td>121,653</td>
<td>0.4%</td>
</tr>
<tr>
<td>Intellectual disabilities and related conditions</td>
<td>335,167</td>
<td>1.1%</td>
<td>339,466</td>
<td>1.1%</td>
<td>339,777</td>
<td>1.1%</td>
<td>342,665</td>
<td>1.1%</td>
<td>353,970</td>
<td>1.1%</td>
</tr>
<tr>
<td>Learning disabilities</td>
<td>23,999</td>
<td>0.1%</td>
<td>27,175</td>
<td>0.1%</td>
<td>30,389</td>
<td>0.1%</td>
<td>37,350</td>
<td>0.1%</td>
<td>59,366</td>
<td>0.2%</td>
</tr>
<tr>
<td>Leukemias and lymphomas</td>
<td>440,672</td>
<td>1.4%</td>
<td>449,712</td>
<td>1.4%</td>
<td>460,919</td>
<td>1.4%</td>
<td>490,255</td>
<td>1.5%</td>
<td>534,535</td>
<td>1.6%</td>
</tr>
<tr>
<td>Liver disease, cirrhosis, and other liver conditions, except hepatitis</td>
<td>1,086,714</td>
<td>3.4%</td>
<td>1,125,345</td>
<td>3.5%</td>
<td>1,167,318</td>
<td>3.6%</td>
<td>1,254,941</td>
<td>3.9%</td>
<td>1,393,667</td>
<td>4.3%</td>
</tr>
<tr>
<td>Migraine and chronic headache</td>
<td>606,438</td>
<td>1.9%</td>
<td>655,760</td>
<td>2.0%</td>
<td>697,287</td>
<td>2.2%</td>
<td>780,849</td>
<td>2.4%</td>
<td>936,146</td>
<td>2.9%</td>
</tr>
<tr>
<td>Mobility impairments</td>
<td>877,107</td>
<td>2.7%</td>
<td>871,941</td>
<td>2.7%</td>
<td>861,166</td>
<td>2.7%</td>
<td>873,355</td>
<td>2.7%</td>
<td>943,326</td>
<td>2.9%</td>
</tr>
<tr>
<td>Multiple sclerosis and transverse myelitis</td>
<td>174,990</td>
<td>0.5%</td>
<td>180,051</td>
<td>0.6%</td>
<td>182,419</td>
<td>0.6%</td>
<td>185,538</td>
<td>0.6%</td>
<td>192,281</td>
<td>0.6%</td>
</tr>
<tr>
<td>Muscular dystrophy</td>
<td>18,820</td>
<td>0.1%</td>
<td>18,631</td>
<td>0.1%</td>
<td>18,239</td>
<td>0.1%</td>
<td>19,466</td>
<td>0.1%</td>
<td>21,991</td>
<td>0.1%</td>
</tr>
<tr>
<td>Obesity</td>
<td>2,776,069</td>
<td>8.7%</td>
<td>3,183,579</td>
<td>9.9%</td>
<td>3,584,911</td>
<td>11.2%</td>
<td>4,126,007</td>
<td>12.8%</td>
<td>5,018,550</td>
<td>15.4%</td>
</tr>
<tr>
<td>Opioid use disorder</td>
<td>304,717</td>
<td>1.0%</td>
<td>347,027</td>
<td>1.1%</td>
<td>394,914</td>
<td>1.2%</td>
<td>484,905</td>
<td>1.5%</td>
<td>680,267</td>
<td>2.1%</td>
</tr>
<tr>
<td>Other developmental delays</td>
<td>35,602</td>
<td>0.1%</td>
<td>39,737</td>
<td>0.1%</td>
<td>41,770</td>
<td>0.1%</td>
<td>44,281</td>
<td>0.1%</td>
<td>43,419</td>
<td>0.1%</td>
</tr>
<tr>
<td>--------------------------------------</td>
<td>---------------</td>
<td>-----------</td>
<td>---------------</td>
<td>-----------</td>
<td>---------------</td>
<td>-----------</td>
<td>---------------</td>
<td>-----------</td>
<td>---------------</td>
<td>-----------</td>
</tr>
<tr>
<td>Peripheral vascular disease (PVD)</td>
<td>3,936,442</td>
<td>12.3%</td>
<td>3,900,376</td>
<td>12.1%</td>
<td>3,866,561</td>
<td>12.1%</td>
<td>3,907,849</td>
<td>12.1%</td>
<td>4,116,589</td>
<td>12.6%</td>
</tr>
<tr>
<td>Personality disorders</td>
<td>186,486</td>
<td>0.6%</td>
<td>191,261</td>
<td>0.6%</td>
<td>190,576</td>
<td>0.6%</td>
<td>257,830</td>
<td>0.8%</td>
<td>443,707</td>
<td>1.4%</td>
</tr>
<tr>
<td>Post-traumatic stress disorder (PTSD)</td>
<td>236,583</td>
<td>0.7%</td>
<td>267,504</td>
<td>0.8%</td>
<td>295,920</td>
<td>0.9%</td>
<td>332,636</td>
<td>1.0%</td>
<td>373,316</td>
<td>1.1%</td>
</tr>
<tr>
<td>Pressure and chronic ulcers</td>
<td>1,603,668</td>
<td>5.0%</td>
<td>1,594,872</td>
<td>5.0%</td>
<td>1,578,437</td>
<td>4.9%</td>
<td>1,565,032</td>
<td>4.9%</td>
<td>1,545,166</td>
<td>4.7%</td>
</tr>
<tr>
<td>Schizophrenia</td>
<td>630,758</td>
<td>2.0%</td>
<td>629,540</td>
<td>2.0%</td>
<td>613,961</td>
<td>1.9%</td>
<td>604,093</td>
<td>1.9%</td>
<td>617,969</td>
<td>1.9%</td>
</tr>
<tr>
<td>Schizophrenia and other psychotic disorders</td>
<td>1,307,122</td>
<td>4.1%</td>
<td>1,309,609</td>
<td>4.1%</td>
<td>1,303,002</td>
<td>4.1%</td>
<td>1,281,148</td>
<td>4.0%</td>
<td>1,151,629</td>
<td>3.5%</td>
</tr>
<tr>
<td>Sensory — blindness and visual impairment</td>
<td>313,192</td>
<td>1.0%</td>
<td>301,718</td>
<td>0.9%</td>
<td>289,004</td>
<td>0.9%</td>
<td>264,081</td>
<td>0.8%</td>
<td>235,727</td>
<td>0.7%</td>
</tr>
<tr>
<td>Sensory — deafness and hearing impairment</td>
<td>1,382,124</td>
<td>4.3%</td>
<td>1,483,259</td>
<td>4.6%</td>
<td>1,567,193</td>
<td>4.9%</td>
<td>1,657,088</td>
<td>5.1%</td>
<td>1,752,465</td>
<td>5.4%</td>
</tr>
<tr>
<td>Sickle cell disease</td>
<td>14,525</td>
<td>0.05%</td>
<td>15,008</td>
<td>0.05%</td>
<td>14,521</td>
<td>0.05%</td>
<td>14,139</td>
<td>0.04%</td>
<td>14,187</td>
<td>0.04%</td>
</tr>
<tr>
<td>Spina bifida and other congenital anomalies of the nervous system</td>
<td>50,487</td>
<td>0.2%</td>
<td>50,777</td>
<td>0.2%</td>
<td>50,651</td>
<td>0.2%</td>
<td>51,010</td>
<td>0.2%</td>
<td>50,979</td>
<td>0.2%</td>
</tr>
<tr>
<td>Spinal cord injury</td>
<td>91,670</td>
<td>0.3%</td>
<td>92,145</td>
<td>0.3%</td>
<td>90,357</td>
<td>0.3%</td>
<td>118,350</td>
<td>0.4%</td>
<td>206,000</td>
<td>0.6%</td>
</tr>
<tr>
<td>Tobacco use</td>
<td>2,501,295</td>
<td>7.8%</td>
<td>2,616,035</td>
<td>8.1%</td>
<td>2,691,524</td>
<td>8.4%</td>
<td>2,761,652</td>
<td>8.6%</td>
<td>2,779,411</td>
<td>8.5%</td>
</tr>
<tr>
<td>Traumatic brain injury and nonpsychotic mental disorders due to brain damage</td>
<td>131,127</td>
<td>0.4%</td>
<td>132,444</td>
<td>0.4%</td>
<td>134,358</td>
<td>0.4%</td>
<td>142,457</td>
<td>0.4%</td>
<td>149,500</td>
<td>0.5%</td>
</tr>
<tr>
<td>Viral hepatitis (general)</td>
<td>374,445</td>
<td>1.2%</td>
<td>382,176</td>
<td>1.2%</td>
<td>385,477</td>
<td>1.2%</td>
<td>398,504</td>
<td>1.2%</td>
<td>418,630</td>
<td>1.3%</td>
</tr>
</tbody>
</table>

* Includes all Medicare beneficiaries who were eligible for or enrolled in Medicare on or after January 1, YYYY. The Chronic Conditions Warehouse (CCW) team calculates period prevalence for these rates: beneficiaries with full or nearly full FFS coverage during the year who had claim(s) for the condition within the condition-specific look-back period (chronic conditions have a one- to five-year look-back period). Refer to the CCW website for more information, including algorithms, for these other chronic or disabling conditions.

** The CCW team may have counted beneficiaries in more than one chronic condition category.

† Denominator: Includes beneficiaries with full or nearly full FFS coverage (i.e., 11 or 12 months of Medicare Parts A and B [or coverage until time of death] and one month or less of health maintenance organization [HMO] coverage).

‡ The CCW team defines numerator as evidence of claims for the condition.

NOTE: The application of different Medicare coverage restrictions/criteria will impact the size of these samples.
### Table B.2.b. Medicare beneficiary prevalence* for other chronic or disabling conditions** using fee-for-service (FFS) claims, 2012–2021

<table>
<thead>
<tr>
<th>Other chronic or disabling condition**</th>
<th>2017 numerator†</th>
<th>2017 rate</th>
<th>2018 numerator†</th>
<th>2018 rate</th>
<th>2019 numerator†</th>
<th>2019 rate</th>
<th>2020 numerator†</th>
<th>2020 rate</th>
<th>2021 numerator†</th>
<th>2021 rate</th>
</tr>
</thead>
<tbody>
<tr>
<td>ADHD, conduct disorders, and hyperkinetic syndrome</td>
<td>328,301</td>
<td>1.0%</td>
<td>340,277</td>
<td>1.1%</td>
<td>347,061</td>
<td>1.1%</td>
<td>336,209</td>
<td>1.1%</td>
<td>316,221</td>
<td>1.1%</td>
</tr>
<tr>
<td>Alcohol use disorders</td>
<td>739,505</td>
<td>2.3%</td>
<td>687,561</td>
<td>2.1%</td>
<td>681,687</td>
<td>2.1%</td>
<td>642,994</td>
<td>2.1%</td>
<td>593,791</td>
<td>2.0%</td>
</tr>
<tr>
<td>Anxiety disorders</td>
<td>5,666,004</td>
<td>17.4%</td>
<td>5,848,948</td>
<td>18.2%</td>
<td>5,972,803</td>
<td>18.7%</td>
<td>5,868,573</td>
<td>18.8%</td>
<td>5,630,819</td>
<td>18.9%</td>
</tr>
<tr>
<td>Autism spectrum disorders</td>
<td>78,205</td>
<td>0.2%</td>
<td>85,325</td>
<td>0.3%</td>
<td>92,751</td>
<td>0.3%</td>
<td>95,920</td>
<td>0.3%</td>
<td>98,374</td>
<td>0.3%</td>
</tr>
<tr>
<td>Bipolar disorder</td>
<td>1,140,178</td>
<td>3.5%</td>
<td>1,138,082</td>
<td>3.5%</td>
<td>1,126,617</td>
<td>3.5%</td>
<td>1,074,815</td>
<td>3.4%</td>
<td>987,123</td>
<td>3.3%</td>
</tr>
<tr>
<td>Cerebral palsy</td>
<td>116,529</td>
<td>0.4%</td>
<td>117,123</td>
<td>0.4%</td>
<td>116,665</td>
<td>0.4%</td>
<td>112,549</td>
<td>0.4%</td>
<td>106,508</td>
<td>0.4%</td>
</tr>
<tr>
<td>Cystic fibrosis and other metabolic developmental disorders</td>
<td>281,760</td>
<td>0.9%</td>
<td>294,437</td>
<td>0.9%</td>
<td>303,244</td>
<td>1.0%</td>
<td>294,266</td>
<td>0.9%</td>
<td>281,013</td>
<td>0.9%</td>
</tr>
<tr>
<td>Depressive disorders</td>
<td>5,533,939</td>
<td>17.0%</td>
<td>5,642,672</td>
<td>17.5%</td>
<td>5,700,967</td>
<td>17.9%</td>
<td>5,509,283</td>
<td>17.7%</td>
<td>5,153,357</td>
<td>17.3%</td>
</tr>
<tr>
<td>Drug use disorders</td>
<td>1,132,782</td>
<td>3.5%</td>
<td>1,165,375</td>
<td>3.6%</td>
<td>1,177,261</td>
<td>3.7%</td>
<td>1,104,745</td>
<td>3.5%</td>
<td>995,801</td>
<td>3.3%</td>
</tr>
<tr>
<td>Epilepsy</td>
<td>909,836</td>
<td>2.8%</td>
<td>906,696</td>
<td>2.8%</td>
<td>894,409</td>
<td>2.8%</td>
<td>854,038</td>
<td>2.7%</td>
<td>782,054</td>
<td>2.6%</td>
</tr>
<tr>
<td>Fibromyalgia, chronic pain, and fatigue</td>
<td>6,969,392</td>
<td>21.5%</td>
<td>7,258,130</td>
<td>22.6%</td>
<td>7,354,751</td>
<td>23.1%</td>
<td>6,969,755</td>
<td>22.3%</td>
<td>6,658,296</td>
<td>22.4%</td>
</tr>
<tr>
<td>Human immunodeficiency virus and/or acquired immunodeficiency syndrome (HIV/AIDS)</td>
<td>119,574</td>
<td>0.4%</td>
<td>115,415</td>
<td>0.4%</td>
<td>110,434</td>
<td>0.3%</td>
<td>104,305</td>
<td>0.3%</td>
<td>94,220</td>
<td>0.3%</td>
</tr>
<tr>
<td>Intellectual disabilities and related conditions</td>
<td>355,445</td>
<td>1.1%</td>
<td>356,057</td>
<td>1.1%</td>
<td>350,938</td>
<td>1.1%</td>
<td>333,342</td>
<td>1.1%</td>
<td>312,976</td>
<td>1.1%</td>
</tr>
<tr>
<td>Learning disabilities</td>
<td>73,427</td>
<td>0.2%</td>
<td>77,321</td>
<td>0.2%</td>
<td>80,590</td>
<td>0.3%</td>
<td>80,591</td>
<td>0.3%</td>
<td>77,809</td>
<td>0.3%</td>
</tr>
<tr>
<td>Leukemias and lymphomas</td>
<td>551,245</td>
<td>1.7%</td>
<td>559,932</td>
<td>1.7%</td>
<td>569,515</td>
<td>1.8%</td>
<td>563,663</td>
<td>1.8%</td>
<td>555,743</td>
<td>1.9%</td>
</tr>
<tr>
<td>Liver disease, cirrhosis, and other liver conditions, except hepatitis</td>
<td>1,507,103</td>
<td>4.6%</td>
<td>1,581,811</td>
<td>4.9%</td>
<td>1,647,361</td>
<td>5.2%</td>
<td>1,629,188</td>
<td>5.2%</td>
<td>1,625,084</td>
<td>5.5%</td>
</tr>
<tr>
<td>Migraine and chronic headache</td>
<td>1,033,856</td>
<td>3.2%</td>
<td>1,075,914</td>
<td>3.3%</td>
<td>1,112,246</td>
<td>3.5%</td>
<td>1,076,400</td>
<td>3.5%</td>
<td>1,048,385</td>
<td>3.5%</td>
</tr>
<tr>
<td>Mobility impairments</td>
<td>977,167</td>
<td>3.0%</td>
<td>969,610</td>
<td>3.0%</td>
<td>959,343</td>
<td>3.0%</td>
<td>916,267</td>
<td>2.9%</td>
<td>837,149</td>
<td>2.8%</td>
</tr>
<tr>
<td>Multiple sclerosis and transverse myelitis</td>
<td>194,724</td>
<td>0.6%</td>
<td>193,738</td>
<td>0.6%</td>
<td>191,762</td>
<td>0.6%</td>
<td>184,657</td>
<td>0.6%</td>
<td>174,449</td>
<td>0.6%</td>
</tr>
<tr>
<td>Muscular dystrophy</td>
<td>22,567</td>
<td>0.1%</td>
<td>22,016</td>
<td>0.1%</td>
<td>21,341</td>
<td>0.1%</td>
<td>19,991</td>
<td>0.1%</td>
<td>18,613</td>
<td>0.1%</td>
</tr>
<tr>
<td>Obesity</td>
<td>5,870,290</td>
<td>18.1%</td>
<td>6,559,576</td>
<td>20.4%</td>
<td>6,701,715</td>
<td>21.0%</td>
<td>6,201,244</td>
<td>19.9%</td>
<td>5,911,014</td>
<td>19.9%</td>
</tr>
<tr>
<td>Opioid use disorder</td>
<td>783,882</td>
<td>2.4%</td>
<td>778,761</td>
<td>2.4%</td>
<td>763,502</td>
<td>2.4%</td>
<td>702,583</td>
<td>2.3%</td>
<td>622,545</td>
<td>2.1%</td>
</tr>
<tr>
<td>Other developmental delays</td>
<td>40,021</td>
<td>0.1%</td>
<td>41,690</td>
<td>0.1%</td>
<td>43,574</td>
<td>0.1%</td>
<td>43,638</td>
<td>0.1%</td>
<td>42,456</td>
<td>0.1%</td>
</tr>
<tr>
<td>Peripheral vascular disease (PVD)</td>
<td>4,113,394</td>
<td>12.7%</td>
<td>4,120,466</td>
<td>12.8%</td>
<td>4,161,955</td>
<td>13.1%</td>
<td>4,005,703</td>
<td>12.8%</td>
<td>3,758,217</td>
<td>12.6%</td>
</tr>
<tr>
<td>Personality disorders</td>
<td>516,426</td>
<td>1.6%</td>
<td>502,527</td>
<td>1.6%</td>
<td>486,044</td>
<td>1.5%</td>
<td>441,185</td>
<td>1.4%</td>
<td>387,502</td>
<td>1.3%</td>
</tr>
<tr>
<td>Post-traumatic stress disorder (PTSD)</td>
<td>397,069</td>
<td>1.2%</td>
<td>420,994</td>
<td>1.3%</td>
<td>439,409</td>
<td>1.4%</td>
<td>429,345</td>
<td>1.4%</td>
<td>401,428</td>
<td>1.3%</td>
</tr>
</tbody>
</table>

* Source for national CMS Medicare and Medicaid research data
** Table B.2.b. Medicare beneficiary prevalence for other chronic or disabling conditions using fee-for-service (FFS) claims, 2012–2021 | Report run date: April 2023 Page 3 of 4
<table>
<thead>
<tr>
<th>Other chronic or disabling condition**</th>
<th>2017 numerator</th>
<th>2017 rate</th>
<th>2018 numerator</th>
<th>2018 rate</th>
<th>2019 numerator</th>
<th>2019 rate</th>
<th>2020 numerator</th>
<th>2020 rate</th>
<th>2021 numerator</th>
<th>2021 rate</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pressure and chronic ulcers</td>
<td>1,508,930</td>
<td>4.6%</td>
<td>1,506,601</td>
<td>4.7%</td>
<td>1,503,293</td>
<td>4.7%</td>
<td>1,471,726</td>
<td>4.7%</td>
<td>1,392,743</td>
<td>4.7%</td>
</tr>
<tr>
<td>Schizophrenia</td>
<td>610,488</td>
<td>1.9%</td>
<td>596,169</td>
<td>1.9%</td>
<td>573,787</td>
<td>1.8%</td>
<td>541,353</td>
<td>1.7%</td>
<td>487,314</td>
<td>1.6%</td>
</tr>
<tr>
<td>Schizophrenia and other psychotic disorders</td>
<td>1,030,212</td>
<td>3.2%</td>
<td>987,563</td>
<td>3.1%</td>
<td>940,228</td>
<td>3.0%</td>
<td>879,982</td>
<td>2.8%</td>
<td>784,276</td>
<td>2.6%</td>
</tr>
<tr>
<td>Sensory — blindness and visual impairment</td>
<td>205,415</td>
<td>0.6%</td>
<td>170,617</td>
<td>0.5%</td>
<td>146,426</td>
<td>0.5%</td>
<td>144,198</td>
<td>0.5%</td>
<td>131,524</td>
<td>0.4%</td>
</tr>
<tr>
<td>Sensory — deafness and hearing impairment</td>
<td>1,828,861</td>
<td>5.6%</td>
<td>1,916,241</td>
<td>6.0%</td>
<td>1,997,233</td>
<td>6.3%</td>
<td>1,907,277</td>
<td>6.1%</td>
<td>1,891,688</td>
<td>6.4%</td>
</tr>
<tr>
<td>Sickle cell disease</td>
<td>13,813</td>
<td>0.04%</td>
<td>13,283</td>
<td>0.04%</td>
<td>12,723</td>
<td>0.04%</td>
<td>12,075</td>
<td>0.04%</td>
<td>10,775</td>
<td>0.0%</td>
</tr>
<tr>
<td>Spina bifida and other congenital anomalies of the nervous system</td>
<td>48,928</td>
<td>0.2%</td>
<td>49,427</td>
<td>0.2%</td>
<td>52,764</td>
<td>0.2%</td>
<td>52,675</td>
<td>0.2%</td>
<td>51,502</td>
<td>0.2%</td>
</tr>
<tr>
<td>Spinal cord injury</td>
<td>246,624</td>
<td>0.8%</td>
<td>241,114</td>
<td>0.7%</td>
<td>243,131</td>
<td>0.8%</td>
<td>227,399</td>
<td>0.7%</td>
<td>212,746</td>
<td>0.7%</td>
</tr>
<tr>
<td>Tobacco use</td>
<td>3,031,387</td>
<td>9.3%</td>
<td>3,213,846</td>
<td>10.0%</td>
<td>3,137,763</td>
<td>9.8%</td>
<td>2,841,035</td>
<td>9.1%</td>
<td>2,495,683</td>
<td>8.4%</td>
</tr>
<tr>
<td>Traumatic brain injury and nonpsychotic mental disorders due to brain damage</td>
<td>150,098</td>
<td>0.5%</td>
<td>150,209</td>
<td>0.5%</td>
<td>148,476</td>
<td>0.5%</td>
<td>136,151</td>
<td>0.4%</td>
<td>121,153</td>
<td>0.4%</td>
</tr>
<tr>
<td>Viral hepatitis (general)</td>
<td>417,015</td>
<td>1.3%</td>
<td>398,665</td>
<td>1.2%</td>
<td>371,130</td>
<td>1.2%</td>
<td>328,954</td>
<td>1.1%</td>
<td>278,395</td>
<td>0.9%</td>
</tr>
</tbody>
</table>

* Includes all Medicare beneficiaries who were eligible for or enrolled in Medicare on or after January 1, YYYY. The Chronic Conditions Warehouse (CCW) team calculates period prevalence for these rates: beneficiaries with full or nearly full FFS coverage during the year who had claims(s) for the condition within the condition-specified lookback period (chronic conditions have a one- to five-year look-back period). Refer to the CCW website for more information, including algorithms, for these other chronic or disabling conditions.

** The CCW team may have counted beneficiaries in more than one chronic condition category.

† Denominator: Includes beneficiaries with full or nearly full FFS coverage (i.e., 11 or 12 months of Medicare Parts A and B [or coverage until time of death] and one month or less of health maintenance organization [HMO] coverage).

‡ The CCW team defines the numerator as evidence of claims for the condition.

NOTE: The application of different Medicare coverage restrictions/criteria will impact the size of these samples.